scholarly journals Predictive value of preoperative C-reactive protein/serum albumin ratio and gamma-glutamyl transpeptidase for early recurrence in patients with hepatocellular carcinoma after resection

2021 ◽  
Vol 29 (17) ◽  
pp. 999-1005
Author(s):  
Xun-Jie Liang ◽  
Zan-Song Huang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Albumin ◽  
Predictive Value ◽  
Early Recurrence ◽  
C Reactive Protein ◽  
Gamma Glutamyl Transpeptidase ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Glutamyl Transpeptidase ◽  
Protein Serum

scholarly journals Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

2020 ◽  
Vol 2020 ◽  
pp. 1-12 ◽  
Author(s):  
JianPing Wu ◽  
WeiLin Mao
Keyword(s):  
Liver Diseases ◽  
Scoring Systems ◽  
Serum Biomarkers ◽  
C Reactive Protein ◽  
Gamma Glutamyl Transpeptidase ◽  
Serum Cystatin C ◽  
Albumin Ratio ◽  
Gamma Glutamyl ◽  
Reactive Protein ◽  
Glutamyl Transpeptidase

A series of predictive scoring systems is available for stratifying the severity of conditions and assessing the prognosis in patients with HBV-related liver diseases. We show nine of the most popular serum biomarkers and their models (i.e., serum cystatin C, homocysteine, C-reactive protein, C-reactive protein to albumin ratio, aspartate aminotransferase to platelet ratio index, fibrosis index based on four factors, gamma-glutamyl transpeptidase to platelet ratio, albumin-bilirubin score, and gamma-glutamyl transpeptidase to albumin ratio) that have gained great interest from clinicians. Compared with traditional scoring systems, these serum biomarkers and their models are easily acquired, simple, and relatively inexpensive. In the present review, we summarize the latest studies focused on these serum biomarkers and their models as diagnostic and prognostic indexes in HBV-related liver diseases.

Serum Albumin and C-Reactive Protein/Albumin Ratio Are Useful Biomarkers of Crohn’s Disease Activity

2016 ◽  
Vol 22 ◽  
pp. 4393-4400 ◽  
Author(s):  
Guangming Qin ◽  
Jiangfeng Tu ◽  
Lingang Liu ◽  
Laisheng Luo ◽  
Jiaqi Wu ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Serum Albumin ◽  
Disease Activity ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Crohn’S Disease Activity

scholarly journals Predictive value of C-Reactive Protein/Albumin ratio in patients with chronic complicated diabetes mellitus

2019 ◽  
Vol 35 (6) ◽  
Author(s):  
Muharrem Bayrak
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Complications ◽  
Predictive Value ◽  
Blood Parameters ◽  
Receiver Operating Curve ◽  
Control Group ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein

Objective: To investigate the relationship between serum C-reactive protein (CRP)/albumin (ALB) ratio and complication occurrence in patients with Type-II diabetes mellitus with at least one chronic complication. Methods: The CAR, demographic characteristics, and other parameters of 108 patients with at least one chronic diabetic complication who attended to the internal medicine outpatient clinic between January 1, 2017, and September 1, 2018, were retrospectively evaluated. Healthy control subjects who did not have any systemic or infectious diseases were also included in the study. I compared the CAR, demographics, and other blood parameters between the two groups were compared. Results: The mean CAR levels were significantly higher in diabetic patients with at least one complication compared to the control group (0.15 [0.07 - 0.29] vs 0.07 [0.07 - 0.07], respectively, p<0.001). There was no significant correlation between CAR and diabetic complications, including neuropathy, nephropathy, coronary artery disease, and retinopathy in the patient group (p>0.05 for all). In the receiver operating curve (ROC) analysis, there was no significant cut-off point for CAR predicting diabetic complications. Conclusions: Although serum CAR levels were significantly higher in complicated diabetic patients compared to controls, any validated CAR value for predicting diabetic complications were not observed. doi: https://doi.org/10.12669/pjms.35.6.618 How to cite this:Bayrak M. Predictive value of C-Reactive Protein/Albumin ratio in patients with chronic complicated diabetes mellitus. Pak J Med Sci. 2019;35(6):1616-1621. doi: https://doi.org/10.12669/pjms.35.6.618 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals C-Reactive Protein to Albumin Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Analysis

2021 ◽  
Author(s):  
Toshifumi Tada ◽  
Takashi Kumada ◽  
Atsushi Hiraoka ◽  
Masashi Hirooka ◽  
Kazuya Kariyama ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Multivariate Analysis ◽  
Progression Free Survival ◽  
C Reactive Protein ◽  
Free Survival ◽  
Albumin Ratio ◽  
Cutoff Value ◽  
Reactive Protein ◽  
Unresectable Hepatocellular Carcinoma

Abstract We investigated the impact of C-reactive protein to albumin ratio (CAR) on predicting outcomes in 522 patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib. We determined the optimal CAR cutoff value with time-dependent receiver operating characteristic curve analysis. Additionally, we clarified the relationship between CAR and liver function or HCC progression. Median overall survival was 20.0 (95% confidence interval (CI), 17.2–22.6) months. The optimal CAR cutoff value was determined to be 0.108. Multivariate analysis showed that high CAR (≥0.108) (hazard ratio (HR), 1.915; 95% CI, 1.495–2.452), Eastern Cooperative Oncology Group performance status ≥1 (HR, 1.429), and α-fetoprotein ≥400 ng/mL (HR, 1.604) were independently associated with overall survival. Cumulative overall survival differed significantly between patients with low versus high CAR (p<0.001). Median progression-free survival was 7.5 (95% CI, 6.7–8.1) months. Multivariate analysis showed that age, CAR ≥0.108 (HR, 1.644; 95% CI, 1.324–2.043), and non-hepatitis B, non-hepatitis C etiology (HR, 0.726) were independently associated with progression-free survival. Cumulative progression-free survival differed significantly between patients with low versus high CAR (p<0.001). CAR values were significantly higher as Japan Integrated Staging score increased (p<0.001). In conclusion, CAR can predict outcomes in patients with unresectable HCC treated with lenvatinib.

Sign in / Sign up

Export Citation Format

Share Document